Literature DB >> 9467659

T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.

O Bruserud1, E Ulvestad, S Berentsen, J Bergheim, I Nesthus.   

Abstract

Intensive chemotherapy for acute leukaemia is followed by a period of severe chemotherapy-induced leukopenia. We used a limiting dilution assay to investigate whether remaining CD4+ and CD8+ T lymphocytes derived from such leukopenic patients could be activated and undergo clonogenic proliferation. The activation signal in our model was accessory cells (irradiated normal peripheral blood mononuclear cells) + phytohaemagglutinin (PHA) + interleukin-2 (IL-2). During severe leukopenia a majority of circulating lymphocytes were CD4+ T cells. Clonogenic proliferating T lymphocytes were detected for all patients. Higher frequencies of clonogenic cells were detected in the CD8+ subset as compared to the CD4+ subset. However, for both subsets frequencies of proliferating cells were decreased compared with healthy individuals. The CD4+ and CD8+ lymphocytes were also capable of proliferation in response to alloactivation, and accessory cells mainly containing acute myelogenous leukaemia blast were efficient as accessory cells for activation. For the CD4+ cells, increased proliferation was detected in the presence of acute myelogenous leukaemia (AML) blasts compared with normal accessory cells. Based on our results we conclude that: (1) although acute leukaemia patients with therapy-induced leukopenia have both a quantitative and a qualitative T-cell defect, (2) the remaining T-cell population includes a subset capable of clonogenic proliferation. However, (3) proliferation of the clonogenic CD4+ cells can be modulated by AML blasts.

Entities:  

Mesh:

Year:  1998        PMID: 9467659     DOI: 10.1046/j.1365-3083.1998.00254.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

Review 1.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

2.  In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum.

Authors:  Oystein Bruserud; Karl Johan Tronstad; Rolf Berge
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-18       Impact factor: 4.553

Review 3.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

4.  Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.

Authors:  Rifca Le Dieu; David C Taussig; Alan G Ramsay; Richard Mitter; Faridah Miraki-Moud; Rewas Fatah; Abigail M Lee; T Andrew Lister; John G Gribben
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

5.  Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.

Authors:  Elisabeth Ersvaer; Knut Liseth; Jørn Skavland; Bjørn Tore Gjertsen; Øystein Bruserud
Journal:  BMC Immunol       Date:  2010-07-09       Impact factor: 3.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.